[go: up one dir, main page]

PE20080537A1 - Derivados de 6-carboxi-normorfinano, su sintesis y usos - Google Patents

Derivados de 6-carboxi-normorfinano, su sintesis y usos

Info

Publication number
PE20080537A1
PE20080537A1 PE2007001008A PE2007001008A PE20080537A1 PE 20080537 A1 PE20080537 A1 PE 20080537A1 PE 2007001008 A PE2007001008 A PE 2007001008A PE 2007001008 A PE2007001008 A PE 2007001008A PE 20080537 A1 PE20080537 A1 PE 20080537A1
Authority
PE
Peru
Prior art keywords
carboxi
synthesis
compound
normorphinan derivatives
normorphinan
Prior art date
Application number
PE2007001008A
Other languages
English (en)
Inventor
Syed M Shah
Kadum A Ali
Fangming Kong
Tianmin Zhu
Charles T Gombar
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of PE20080537A1 publication Critical patent/PE20080537A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I EN FORMA DE SAL SELECCIONADA DE BISULFATO, TARTRATO, NITRATO, SULFONATO, FORMIATO, CARBOXILATO, ENTRE OTROS. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO INHIBE LOS EFECTOS SECUNDARIOS DEL TRATAMIENTO DE OPIOIDES TALES COMO INIHIBICION DE LA MOTILIDAD INTESTINAL, DISFUNCION GASTROINTESTINAL, CONSTIPACION, EVACUACION INCOMPLETA, DISTENCION ABDOMINAL, ENTRE OTROS
PE2007001008A 2006-08-04 2007-08-02 Derivados de 6-carboxi-normorfinano, su sintesis y usos PE20080537A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83568706P 2006-08-04 2006-08-04

Publications (1)

Publication Number Publication Date
PE20080537A1 true PE20080537A1 (es) 2008-06-23

Family

ID=38649979

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001008A PE20080537A1 (es) 2006-08-04 2007-08-02 Derivados de 6-carboxi-normorfinano, su sintesis y usos

Country Status (15)

Country Link
US (1) US7501434B2 (es)
EP (1) EP2046800B1 (es)
JP (1) JP2009545629A (es)
CN (1) CN101522684A (es)
AR (1) AR062211A1 (es)
AT (1) ATE486076T1 (es)
AU (1) AU2007281408A1 (es)
BR (1) BRPI0715342A2 (es)
CA (1) CA2660027A1 (es)
CL (1) CL2007002272A1 (es)
DE (1) DE602007010151D1 (es)
MX (1) MX2009001282A (es)
PE (1) PE20080537A1 (es)
TW (1) TW200815451A (es)
WO (1) WO2008016704A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
EP2368553B1 (en) 2003-04-08 2014-12-31 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
AR057325A1 (es) * 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
EP3263571B2 (en) 2007-03-29 2023-08-23 Progenics Pharmaceuticals, Inc. Crystal form of (r)-n-methylnaltrexone bromide and uses thereof
JP5469593B2 (ja) 2007-03-29 2014-04-16 ワイス・エルエルシー 末梢性オピオイド受容体アンタゴニストおよびその使用
US8546418B2 (en) 2007-03-29 2013-10-01 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof
CN101959892B (zh) 2008-02-06 2014-01-08 普罗热尼奇制药公司 (r),(r)-2,2’-二-甲基纳曲酮的制备和用途
US8685995B2 (en) 2008-03-21 2014-04-01 The University Of Chicago Treatment with opioid antagonists and mTOR inhibitors
JP5985824B2 (ja) 2008-07-01 2016-09-06 ザ ユニヴァーシティー オヴ シカゴ オピオイド受容体アンタゴニスト含有の粒子および使用方法
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
US9192570B2 (en) 2013-12-20 2015-11-24 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
CA2934913A1 (en) * 2013-12-26 2015-07-02 Purdue Pharma L.P. Ring-contracted morphinans and the use thereof
CN109096190B (zh) * 2017-06-21 2021-07-02 中国医学科学院药物研究所 一种青藤碱衍生物及其制备方法、用途和药物组合物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4176186A (en) * 1978-07-28 1979-11-27 Boehringer Ingelheim Gmbh Quaternary derivatives of noroxymorphone which relieve intestinal immobility
US4719215A (en) 1986-03-07 1988-01-12 University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US4861781A (en) 1986-03-07 1989-08-29 The University Of Chicago Quaternary derivatives of noroxymorphone which relieve nausea and emesis
US5102887A (en) 1989-02-17 1992-04-07 Arch Development Corporation Method for reducing emesis and nausea induced by the administration of an emesis causing agent
CA2143864C (en) * 1993-07-23 2006-01-24 Hiroshi Nagase Morphinan derivatives and pharmaceutical use thereof
IT1269826B (it) 1994-05-24 1997-04-15 Paolo Minoia Uso di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino-mediate
US5972954A (en) 1997-11-03 1999-10-26 Arch Development Corporation Use of methylnaltrexone and related compounds
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
MXPA05004759A (es) * 2002-11-08 2005-08-02 Mallinckrodt Inc Proceso para la preparacion de sales alcaloides n-alquil morfinan cuaternarias.
EP2368553B1 (en) 2003-04-08 2014-12-31 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
US8946262B2 (en) 2003-12-04 2015-02-03 Adolor Corporation Methods of preventing and treating gastrointestinal dysfunction
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
TW200817048A (en) 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
EP2097418A1 (en) 2006-11-22 2009-09-09 Progenics Pharmaceuticals, Inc. Processes for synthesizing quaternary 4,5-epoxy-morphinan analogs and isolating their n-stereoisomers
CA2670136A1 (en) 2006-11-22 2008-05-29 Progenics Pharmaceuticals, Inc. 7,8-saturated-4,5-epoxy-morphinanium analogs
AU2007329590A1 (en) 2006-11-22 2008-06-12 Progenics Pharmaceuticals, Inc. N-oxides of 4,5-epoxy-morphinanium analogs
JP5469593B2 (ja) 2007-03-29 2014-04-16 ワイス・エルエルシー 末梢性オピオイド受容体アンタゴニストおよびその使用
US8546418B2 (en) 2007-03-29 2013-10-01 Progenics Pharmaceuticals, Inc. Peripheral opioid receptor antagonists and uses thereof

Also Published As

Publication number Publication date
TW200815451A (en) 2008-04-01
CL2007002272A1 (es) 2008-04-18
US7501434B2 (en) 2009-03-10
EP2046800A1 (en) 2009-04-15
BRPI0715342A2 (pt) 2015-03-24
MX2009001282A (es) 2009-02-11
WO2008016704A1 (en) 2008-02-07
US20080064744A1 (en) 2008-03-13
CN101522684A (zh) 2009-09-02
JP2009545629A (ja) 2009-12-24
AU2007281408A1 (en) 2008-02-07
DE602007010151D1 (de) 2010-12-09
CA2660027A1 (en) 2008-02-07
AR062211A1 (es) 2008-10-22
ATE486076T1 (de) 2010-11-15
EP2046800B1 (en) 2010-10-27

Similar Documents

Publication Publication Date Title
PE20080537A1 (es) Derivados de 6-carboxi-normorfinano, su sintesis y usos
PE20090700A1 (es) Compuestos heterociclicos como antagonistas del receptor opioide periferico
UY30130A1 (es) Derivados de n-heteroaril-carboxamidas triciclicas que contienen un resto bencimidazol, su preparacion y su aplicacion en terapeutica.
AR073524A1 (es) Piridopirimidinonas inhibidores de pi3k a y m tor
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
UY29938A1 (es) Derivados de pirido-, pirazo- y pirimido-pirimidina y su uso como inhibidores de mtor
AR050952A1 (es) Derivados de indazolona; procesos para su obtencion; composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta - hsd1.
FI3429571T3 (fi) Lsd1-inhibiittorien yhdistelmiä käytettäväksi kasvaintautien hoitamisessa
PE20120776A1 (es) Estructuras cristalinas de dapagliflozin y sus procesos de preparacion
UY35641A (es) PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO)
UY31127A1 (es) Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841
CU24099B1 (es) Derivados de sulfonamida para el tratamiento del dolor
CR9214A (es) 2-fenilindoles como antagonistas del receptor de la prostaglandina d2
NZ598972A (en) Spiro-indoline-piperidine derivatives as selective GPR-40 activators for treating diabetes
MX343264B (es) Ciertas amino-piridazinas, composiciones de las mismas y metodos de uso de los mismos.
CR11150A (es) Compuestos de bencimidazol
AR073598A1 (es) Pirrolidinas 2-carboxamidas sustituidas, composiciones farmaceuticas que las contienen y uso de las mismas como agentes anticancer.
PE20120052A1 (es) Polimorfos de (s)-3-amino-metil-7-(3-hidroxi-propoxi)-3h-benzo-[c][1,2]-oxaborol-1-ol
CO6480931A2 (es) Sulfonamidas heterocíclicas, usos y composiciones farmacéuticas de las mismas.
PE20120545A1 (es) Composicion farmaceutica que comprende la forma i cristalina de la sal clorhidrato monohidrato de (5s,8s)-8-[{(1r)-1-(3,5-bis-(trifluorometil)fenil)-etoxi}-metil]-8-fenil-1,7-diazaspiro[4,5]decan-2-ona
IN2012DN00765A (es)
MX360330B (es) Regimen de administracion para nitrocatecoles.
EA201600619A1 (ru) Хромен и 1,1а, 2,7в-тетрагидроциклопропа[с]хромен пиридопиразиндионы в качестве модулятора гамма-секретазы
CR11360A (es) Benzotiazoles como moduladores del receptor de grelina
AR090806A1 (es) Glucosidos de pirazol y su utilizacion en el tratamiento de la diabetes tipo i y ii

Legal Events

Date Code Title Description
FX Voluntary withdrawal